Dr. Michael Main, MD
Allergy & Immunology (Allergy & Immunology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- New York University School of Medicine (2019)
- Years since graduation
- 7
- In the NPI registry since
- 2019
- Medicare patients seen, 2024
- 40
Licensed in California since 2022, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2019Medical school: New York University School of Medicine
- 2019Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology (Internal Medicine) Physician primary
CA license A178576 (first issued 2022; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Regents of the University of California - UCSF (80 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 40
- Services billed
- 732
- Patients’ average age
- 73
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 9 companies reported 27 payments worth $674 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $235 |
|---|---|
| GlaxoSmithKline, LLC. | $143 |
| Regeneron Healthcare Solutions, Inc. | $68.34 |
| Amgen Inc. | $54.49 |
| Takeda Pharmaceuticals U.S.A., Inc. | $43.67 |
| Novartis Pharmaceuticals Corporation | $39.42 |
| Octapharma USA, Inc. | $33.36 |
| Hospira, Inc. | $29.74 |
| Food and Beverage | $674 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.